BrightGene Bio Medical Technology C (688166) - Total Liabilities

Latest as of June 2025: CN¥2.80 Billion CNY ≈ $409.38 Million USD

Based on the latest financial reports, BrightGene Bio Medical Technology C (688166) has total liabilities worth CN¥2.80 Billion CNY (≈ $409.38 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

BrightGene Bio Medical Technology C - Total Liabilities Trend (2016–2024)

This chart illustrates how BrightGene Bio Medical Technology C's total liabilities have evolved over time, based on quarterly financial data. See BrightGene Bio Medical Technology C short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

BrightGene Bio Medical Technology C Competitors by Total Liabilities

The table below lists competitors of BrightGene Bio Medical Technology C ranked by their total liabilities.

Company	Country	Total Liabilities
Delek Logistics Partners LP NYSE:DKL	USA	$2.93 Billion
Worthington Industries Inc NYSE:WOR	USA	$790.31 Million
SASA Polyester Sanayi AS IS:SASA	Turkey	TL150.95 Billion
Harley-Davidson Inc NYSE:HOG	USA	$4.17 Billion
Siriuspoint Ltd NYSE:SPNT	USA	$10.18 Billion
Northeast Securities Co Ltd SHE:000686	China	CN¥106.26 Billion
Genius Electronic Optical Co Ltd TW:3406	Taiwan	NT$18.70 Billion
Hand Enterprise Solutions Co SHE:300170	China	CN¥1.08 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down BrightGene Bio Medical Technology C's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of BrightGene Bio Medical Technology C.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.33	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.13	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.52	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how BrightGene Bio Medical Technology C's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for BrightGene Bio Medical Technology C (2016–2024)

The table below shows the annual total liabilities of BrightGene Bio Medical Technology C from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥2.73 Billion ≈ $399.04 Million	+4.31%
2023-12-31	CN¥2.61 Billion ≈ $382.55 Million	+8.05%
2022-12-31	CN¥2.42 Billion ≈ $354.06 Million	+97.04%
2021-12-31	CN¥1.23 Billion ≈ $179.69 Million	+210.70%
2020-12-31	CN¥395.23 Million ≈ $57.83 Million	+265.24%
2019-12-31	CN¥108.21 Million ≈ $15.83 Million	+2.55%
2018-12-31	CN¥105.52 Million ≈ $15.44 Million	+33.76%
2017-12-31	CN¥78.89 Million ≈ $11.54 Million	-51.91%
2016-12-31	CN¥164.05 Million ≈ $24.01 Million	--

About BrightGene Bio Medical Technology C

SHG:688166 China Biotechnology

Market Cap

$2.68 Billion

CN¥18.28 Billion CNY

Market Cap Rank

#5372 Global

#1033 in China

Share Price

CN¥43.21

Change (1 day)

+7.01%

52-Week Range

CN¥40.25 - CN¥116.49

All Time High

CN¥116.49